How's Legend Biotech doing these days?
In our cell therapy market deck, you will find everything you need to understand the market
SUMMARY
How's Legend Biotech doing these days? Legend Biotech is doing well right now, because Carvykti is still scaling fast, manufacturing looks much stronger, profitability is getting close, and LB2501 has finally made the pipeline interesting again.
The most important thing is that Legend’s story no longer rests only on biotech promise. Q1 2026 Carvykti sales, market launches, treatment-site expansion, and manufacturing metrics all show real execution, not just investor excitement.
Carvykti still looks like the BCMA CAR-T to beat. More than 10,000 patients have been treated across clinical and commercial use, and earlier-line adoption is rising, which usually means the product is becoming part of the main treatment pathway.
The growth mix is especially telling. U.S. sales are still increasing, but ex-U.S. sales are growing much faster, which suggests the next leg of growth is coming from geographic expansion rather than only deeper U.S. penetration.
Manufacturing is probably the most underappreciated improvement. A 99% manufacturing success rate, about 29-day median turnaround, and more than 95% on-time order release make the old supply-bottleneck bear case much less scary.
Profitability now feels credible, although Legend is not acting like a company that wants to coast. The company had about $834.6M in cash at the end of Q1 2026 and narrowed adjusted net loss sharply, but the June 2026 equity raise shows management still wants extra strategic firepower.
LB2501 changed the pipeline conversation. The early in vivo CAR-T data are tiny, but a 100% objective response rate in the higher-dose cohort, clean early safety, and no lymphodepletion make it a real strategic upside rather than a routine pipeline footnote.
The competitive threat has also become clearer. Abecma no longer looks like the main pressure point; Gilead and Arcellx’s anito-cel is the asset to watch because it is aimed directly at Carvykti’s safety and convenience vulnerabilities.
Safety is now a serious watch item, but not a thesis breaker today. The FDA boxed warning for IEC-EC matters, especially as Carvykti moves earlier, yet recent commercial growth suggests physicians are still using the product despite the added caution.
The legal and geopolitical overhangs are real but secondary for now. The European IP fight, GenScript history, and China-linked perception risk matter, but Legend’s U.S. manufacturing footprint, New Jersey positioning, and commercial-scale hires make the company look more U.S.-centered and operationally mature.
The clean conclusion is that Legend Biotech looks better today than it did a year ago. It is still heavily dependent on Carvykti, but the company now has stronger supply, broader geography, a more believable profit path, and a second story investors can actually care about.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Is Legend Biotech still growing fast these days?
Legend Biotech is still growing fast, and the recent Carvykti numbers look strong enough to say demand is not the issue right now.
Carvykti did about $597M in Q1 2026 net trade sales, up 62% year over year. That is already a big number for a CAR-T product, but the more interesting part is where the growth came from. U.S. sales were still up 36%, while ex-U.S. sales were up 222%.
That tells us Legend and J&J are not just squeezing more out of the original U.S. launch. They are still opening new geographies.
The company also launched Carvykti recently in Italy, Poland, the Czech Republic, and Australia. That brought the product to more than 300 treatment sites across 18 markets. For a normal drug, new market launches are nice. For a CAR-T therapy, they matter more because every extra site can remove a real bottleneck.
There is a useful order of magnitude here. Q1 2026 Carvykti sales were already bigger than Abecma’s old quarterly peak, and the product is now running at a multi-billion-dollar annualized pace. That does not mean growth will stay linear, but it does mean Legend is playing in a much larger commercial zone than most cell-therapy companies ever reach.
So, Legend Biotech still looks like a growth company today. The growth is not coming from hype anymore. It is showing up in shipped product, new countries, and treatment-center expansion.
Is Legend Biotech’s Carvykti still the main BCMA CAR-T to beat now?
Legend Biotech’s Carvykti still looks like the BCMA CAR-T to beat today, even though the next serious challenger is finally getting close.
The most concrete signal is usage. Carvykti has now treated more than 10,000 patients across clinical and commercial use. In cell therapy, that matters. It means hospitals know the workflow, physicians know the side effects, and payers have already built some muscle memory around reimbursement.
The second signal is that Carvykti is moving earlier in the treatment journey. In the U.S., second- and third-line patients represented 41% of apheresis volume in Q1 2026, versus 29% a year earlier. That is not a small mix shift. Earlier-line adoption usually means the product is becoming part of the main treatment pathway, rather than staying a late-rescue option.
The third signal is competitive. Abecma is still around, but it no longer looks like the main pressure point. The real pressure now is Gilead/Arcellx’s anito-cel, because that product is late-stage, backed by Kite’s cell-therapy infrastructure, and being framed around a cleaner safety profile.
Still, Carvykti has the installed base today. It has the sites, the real-world experience, the earlier-line position, and the sales momentum. A new entrant can still win share, but it has to fight against habits that are already forming.
Carvykti is still leading. Legend’s problem is no longer proving the product matters; it is defending the lead before the market gets more crowded.
If you want more recent data on this point, please see our latest cell therapy market report.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Is Legend Biotech finally fixing the manufacturing bottleneck?
Legend Biotech has made real progress on manufacturing lately, and this is probably one of the most important underappreciated signals.
The company reported a 99% manufacturing success rate in Q1 2026. It also reported a median turnaround time of about 29 days and more than 95% on-time order releases. Those are not abstract operational metrics. For an autologous CAR-T drug, they decide whether a patient can actually get treated.
This is where the interpretation matters. A CAR-T company can have great clinical data and still disappoint commercially if the manufacturing chain is unreliable. Here, Legend is showing the opposite pattern: the commercial numbers are rising while the production metrics are also improving.
The Raritan facility is another signal. Legend has described the expanded site as the largest cell-therapy manufacturing facility in the U.S., with installed capacity to support up to 10,000 patients annually. That gives the company a stronger answer to the old bear case that Carvykti demand would always outrun supply.
There is one caveat. Gross margin moved around because of manufacturing ramp costs. So this is not a magical scale-up where capacity expands and costs disappear. But the direction is good: more successful batches, faster release, and more predictable supply.
Legend Biotech’s manufacturing story looks much better now. It is still a hard business, but it no longer looks like the obvious ceiling on Carvykti.
Is Legend Biotech close to profitability now?
Legend Biotech is close enough to profitability that the claim now feels credible, not decorative.
The company ended Q1 2026 with about $834.6M in cash, cash equivalents, and time deposits. Management said that cash should fund the company beyond 2026, when it expects to reach company-wide profit. That is a strong statement for a cell-therapy company, because this category usually burns cash for a long time.
The income statement is also moving in the right direction. Collaboration revenue reached about $298.4M in Q1 2026, driven by Carvykti sales under the J&J/Janssen collaboration. Net loss narrowed, and adjusted net loss was only about $10.5M in the quarter. That is not profitability yet, but it is close enough to make the 2026 target believable.
The more subtle signal is R&D mix. Spending on mature cilta-cel work is coming down as major trial dosing phases conclude, while pipeline spending is becoming more important. That is what we want to see at this stage: the flagship product starts carrying more of the company while new programs get funded.
But the June 2026 equity raise stops us from saying the company is fully self-funding. Legend priced 7.7M ADSs at $29.35, for about $226M in gross proceeds. That is not what a desperate company does, but it does show management still wants more capital while the market window is open.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Why did Legend Biotech raise money again now?
Legend Biotech’s June 2026 raise looks opportunistic, not like a distress signal.
The timing is the biggest clue. Legend raised money right after several positive updates: strong Q1 results, ASCO data, EHA in vivo CAR-T data, and a sharp stock reaction to LB2501. If a company raises after bad data, we worry. If it raises after the stock jumps on genuinely new pipeline data, that usually tells us management is using the moment.
The size also matters. About $226M in gross proceeds is meaningful, but it is not a rescue amount compared with the $834.6M cash balance Legend had at the end of Q1 2026. The company already said it had runway beyond 2026. So the raise is better read as extra fuel for pipeline development, manufacturing, and strategic flexibility.
There is still a fair investor pushback. If Legend is so close to profitability, why dilute shareholders now? The best answer is that the company does not want to be valued only on Carvykti. LB2501 just gave management a chance to argue that Legend can become a broader in vivo and cell-therapy platform.
Finally, the bookrunners also tell us this was a serious institutional raise: Morgan Stanley, Jefferies, Citi, and Deutsche Bank were involved. That does not make the raise good by itself, but it supports the idea that Legend used a real financing window, not a weak one.
So we can conclude that the raise is mildly annoying but not alarming.
Is Legend Biotech’s pipeline finally interesting again?
Legend Biotech’s pipeline is interesting again, mainly because LB2501 changed the conversation in June 2026.
LB2501 is the big new signal. In the higher-dose cohort, the drug showed a 100% objective response rate in 6 of 6 patients with relapsed/refractory B-cell non-Hodgkin lymphoma, with 5 of 6 complete responses. It is a tiny early study, so we should not treat it like registrational proof. But for first human in vivo CAR-T data, it was the kind of result that makes investors stop scrolling.
The mechanism is what makes it more than another oncology readout. LB2501 is designed to create CAR-T cells inside the patient after a single IV infusion. No personalized cell manufacturing. No lymphodepleting chemotherapy. If that keeps working, it attacks the two biggest problems in traditional CAR-T: time and complexity.
The safety signal was also clean so far. Legend reported no dose-limiting toxicities, no serious adverse events, no ICANS, and no deaths. CRS and infusion reactions were grade 1–2, and CRS did not require glucocorticoids. Again, early data. But clean early safety matters a lot when the whole pitch is “simpler CAR-T.”
LB2102 is less exciting but still worth tracking. The DLL3-targeted CAR-T in small-cell lung cancer and large-cell neuroendocrine carcinoma showed 28.6% ORR and 78.6% disease control at higher dose levels. That is clearly a signal that Legend can keep a solid-tumor CAR-T program alive in a field where many others have failed.
If you want more recent data on this point, please see our latest cell therapy market report.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Is in vivo CAR-T becoming a real Legend Biotech upside now?
In vivo CAR-T is now a real upside for Legend Biotech, not just a slide in the pipeline section.
The reason is simple: LB2501 tries to remove the factory from the patient journey. Traditional CAR-T means cells leave the patient, get engineered, pass release testing, and come back weeks later. LB2501 tries to make the body do the CAR-T generation directly. If that works beyond early lymphoma data, the commercial model changes.
Legend’s CEO Ying Huang made the point directly in recent press coverage: instead of doing the engineering in a factory, Legend is moving it into the body. He also suggested manufacturing cost could eventually be very different from traditional CAR-T, potentially by an order of magnitude. That is the kind of comment investors listen to because it connects clinical data to a business model.
The market reaction also tells us this was not treated as a routine update. Legend’s stock jumped more than 40% after the early LB2501 data, one of its biggest single-day moves. That kind of move does not happen because investors suddenly remembered Carvykti exists. It happened because the market saw a possible second story.
The broader M&A context makes this even more important. Big pharma has been buying into next-generation cell therapy and in vivo approaches. Gilead bought Arcellx to control anito-cel. Lilly agreed to buy Kelonia after early in vivo-style excitement. J&J already works with Legend and has pressure to stay close to the next wave.
Is Carvykti safety becoming a real problem lately?
Carvykti safety is a real thing to watch lately, but it does not look like it is breaking the product.
The FDA added a boxed warning in October 2025 for immune effector cell-associated enterocolitis, or IEC-EC. That is serious because it can be delayed, severe, and in some cases life-threatening. It matters even more because Carvykti is moving earlier in treatment, where doctors may be more cautious about long-tail risks.
Legend and J&J pushed back with more data at ASCO 2026. A multi-study analysis reported IEC-EC incidence of 1.2% across Carvykti clinical trials. That is low, and it helps turn a scary warning into something physicians can quantify.
But real-world data add nuance. A Mayo Clinic retrospective study found 9 IEC-EC cases among 229 cilta-cel patients, or about 3.9%. Another J&J medical summary referenced retrospective work on 27 patients who developed IEC-EC, with median diarrhea onset around 82 days. That timing matters because the problem can appear well after the infusion window.
Safety is now part of every serious Carvykti conversation. But the recent growth numbers tell us physicians are still using the product.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
Is Gilead’s anito-cel becoming a real threat to Legend Biotech now?
Gilead’s anito-cel is becoming the real competitive threat to Legend Biotech, much more than Abecma today.
The cleanest signal is Gilead’s $7.8B acquisition of Arcellx in February 2026. Big pharma does not pay that much for a nice-to-have asset. Gilead already had Kite, already had cell-therapy infrastructure, and still decided it wanted full control of anito-cel. That tells us it sees a major BCMA opportunity.
Anito-cel’s pitch is also aimed exactly at Carvykti’s soft spot: safety. Recent iMMagine-1 data have been framed around deep responses with a predictable safety profile and no delayed neurotoxicity signals in the highlighted follow-up. That is important because Carvykti’s delayed neurotoxicity and IEC-EC concerns are precisely where a competitor would try to wedge in.
There was also a telling moment in late 2025: J&J and Legend withdrew an ASH abstract comparing Carvykti with anito-cel after methodological criticism. That does not prove anything clinically, but it shows the competitive debate is already sensitive. When companies start fighting over cross-trial comparisons, it usually means the market is taking the challenger seriously.
Still, anito-cel has to launch into a market where Carvykti is already deeply embedded. Legend has the patient base, the earlier-line use, the treatment sites, and the J&J commercial machine. That is a big head start.
If you want more recent data on this point, please see our latest cell therapy market report.
Is Legend Biotech getting dragged into messy legal fights now?
Legend Biotech now has a real European IP fight around Carvykti, and it is worth watching even if it is not hurting the business yet.
In January 2026, 2seventy bio filed a UPC patent case in Brussels against J&J entities and Legend Biotech over Carvykti. Bristol Myers Squibb is behind 2seventy after acquiring the company, so this is really part of the broader BMS/J&J fight in BCMA CAR-T.
The patent at issue relates to BCMA-targeted CAR-T technology in Europe. J&J has responded with a UK revocation action, and the patent is also being challenged at the European Patent Office. That means the dispute is not just one isolated complaint; it is a multi-front attempt to pressure Carvykti’s European position.
The timing is not random. Carvykti is expanding outside the U.S., and Europe is becoming more meaningful. As seen above, ex-U.S. sales rose very sharply in Q1 2026. When a product starts becoming more commercially relevant in a region, IP pressure tends to become more valuable for rivals.
For now, though, there is no visible sign that the lawsuit has slowed current sales, site expansion, or management guidance. It is a legal overhang, not an operating wound.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
Is Legend Biotech becoming more U.S.-centered now?
Legend Biotech is clearly trying to look more U.S.-centered now, and that matters because the company still carries some China-linked perception risk.
The company’s current public positioning leans heavily into New Jersey headquarters, U.S. manufacturing, and global operations. The Raritan expansion is central to that story. It gives Legend a real U.S. industrial footprint, not just a U.S. listing and investor-relations presence.
The GenScript relationship is still part of the company’s history, but the control story has changed. GenScript deconsolidated Legend after losing majority voting power in 2024. That reduced the perception that Legend was simply a controlled subsidiary of a Chinese biotech parent.
The leadership and hiring signals also point in the same direction. Legend added Carlos Santos as CFO in 2025 after his role as CFO for U.S. Oncology at AstraZeneca. Alan Bash was appointed President of Carvykti earlier, with responsibility across commercial, technical operations, and quality for the franchise. Those are actual commercial-scale pharma hires.
Lately, the careers signal also looks operationally heavy in the U.S., with Raritan roles around QC, microbiology, QA shop floor, and manufacturing. That is exactly where the company needs people if the priority is reliable commercial supply.
Is Legend Biotech being run like a real commercial pharma now?
Legend Biotech is increasingly being run like a specialized commercial pharma company, not a science project with one lucky asset.
The first signal is role design. Creating a dedicated President of Carvykti role was a practical move. Carvykti is already too big to be managed like one pipeline program among others. It needs its own commercial, quality, manufacturing, and execution owner.
The second signal is finance. Bringing in a former AstraZeneca U.S. Oncology CFO makes sense for a company trying to hit profitability while managing a global oncology franchise. The job is no longer just “raise money for trials.” It is margin, collaboration economics, manufacturing ramp, and investor discipline.
The third signal is headcount and open roles. Legend has crossed 3,000 employees, and its hiring page has been showing many operational jobs around quality and manufacturing. For a CAR-T company, those are not boring back-office roles. They are the people who decide whether growth can happen safely and repeatedly.
The fourth signal is how the company talks now. The language has shifted from pure innovation to execution: manufacturing success, on-time release, site expansion, profitability, and global launches. That is exactly the vocabulary of a company trying to prove it can scale.
Finally, Legend Biotech now looks like a company with two clocks running at once. One clock is commercial: keep Carvykti scaling. The other is platform: prove LB2501 can be bigger than a small early trial. That is a much more mature operating setup than the company had a few years ago.
If you want more recent data on this point, please see our latest cell therapy market report.
This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market
So, how is Legend Biotech doing these days?
Legend Biotech is doing well right now. The company has stronger commercial momentum, better manufacturing metrics, a credible path toward profitability, and the first pipeline update in a while that actually changed the market conversation.
The main thing we learned from digging is that the story has recently widened. Carvykti is still the engine, but LB2501 has become the new upside. That matters because investors hate one-product biotech stories, even when the product is great. Legend now has at least one early asset that can make people ask a different question: “could this company become a broader cell-therapy platform?”
The risks are also clearer now. Gilead/Arcellx is the competitive threat to watch. IEC-EC is the safety issue to monitor. The 2seventy/BMS European IP case is the legal overhang. The June 2026 raise is the financing signal that says management still wants extra firepower.
But none of those risks currently changes the conclusion. Legend Biotech looks better today. Carvykti is scaling, manufacturing is improving, in vivo CAR-T just became investable, and competitors are now taking Legend seriously enough to spend billions or sue around it.
If you want more recent data on this point, please see our latest cell therapy market report.
| Question checked | Answer | Signals behind the answer |
|---|---|---|
| Is Legend still growing fast these days? | Yes. Growth still looks real and broadening. | Carvykti Q1 2026 sales around $597M; +62% YoY; ex-U.S. sales +222%; new launches in Italy, Poland, Czech Republic, and Australia; 18 markets and 300+ sites. |
| Is Carvykti still the main BCMA CAR-T to beat? | Yes. Carvykti still leads today. | 10,000+ treated patients; U.S. second/third-line apheresis mix rose to 41%; Abecma looks less threatening; anito-cel is the bigger future risk. |
| Is manufacturing getting fixed now? | Yes. The bottleneck looks much less scary. | 99% manufacturing success; about 29-day median turnaround; >95% on-time order release; Raritan expansion to support up to 10,000 patients annually. |
| Is Legend close to profitability now? | Yes, but still building aggressively. | $834.6M cash; Q1 collaboration revenue around $298.4M; adjusted net loss about $10.5M; company-wide profit target beyond 2026 runway. |
| Why did Legend raise money again now? | It looks opportunistic, not distressed. | $226M June 2026 gross proceeds; 7.7M ADSs at $29.35; raise came after LB2501 excitement and strong Q1 data; major bank bookrunners. |
| Is Legend’s pipeline interesting again? | Yes. LB2501 changed the tone. | LB2501 100% ORR at higher dose; 83.3% CR; no lymphodepletion; no DLTs, SAEs, ICANS, or deaths; LB2102 showed 28.6% ORR and 78.6% DCR at higher doses. |
| Is in vivo CAR-T real upside now? | Yes. It is now strategic upside. | LB2501 generates CAR-T cells inside the body; stock jumped >40%; CEO framed it as moving the factory into the patient; broader big-pharma M&A in in vivo/cell therapy. |
| Is Carvykti safety a real problem lately? | It is a real watch item, not a thesis breaker. | FDA boxed warning for IEC-EC in October 2025; ASCO 2026 multi-study incidence of 1.2%; Mayo real-world signal around 3.9%; continued commercial growth despite warning. |
| Is anito-cel becoming a real threat? | Yes. Gilead/Arcellx is the main competitor now. | Gilead’s $7.8B Arcellx deal; anito-cel framed around cleaner safety; iMMagine data; J&J/Legend withdrew ASH comparison abstract. |
| Is litigation getting messy now? | Yes, but no current operating damage. | 2seventy/BMS UPC case in Brussels; J&J UK revocation action; EPO challenge; litigation overlaps with ex-U.S. Carvykti expansion. |
| Is Legend becoming more U.S.-centered now? | Yes. The center of gravity looks more U.S./global. | New Jersey headquarters; Raritan manufacturing expansion; GenScript deconsolidation; U.S.-heavy commercial and operations hiring. |
| Is Legend being run like commercial pharma now? | Yes. The organization looks more mature. | President of Carvykti role; former AstraZeneca U.S. Oncology CFO hire; 3,000+ employees; hiring around QC, microbiology, QA, and manufacturing. |
This chart, featured in our cell therapy market deck, shows how CAR-T cell therapy technology has evolved over time
OUR METHODOLOGY
This analysis tests how Legend Biotech is doing today by looking across the signals that actually shape the company’s current position: Carvykti growth, product leadership, manufacturing execution, profitability, financing, pipeline depth, safety, competition, legal risk, geographic positioning, and organizational maturity.
We did not treat this as a single-metric question. Legend Biotech is now being pulled between several stories at once: Carvykti’s commercial scale-up, manufacturing execution, a more credible path toward profitability, new dilution, early in vivo CAR-T excitement, and rising competition from anito-cel.
For each dimension, we looked for recent signals that showed what is changing now, not just what the company has historically been known for. We gave more weight to evidence tied to real execution, such as sales growth, treatment-site expansion, patient usage, manufacturing success rates, release timing, cash runway, financing terms, clinical readouts, regulatory updates, and competitor actions.
We also separated signals that change the thesis from signals that simply need to be watched. LB2501 matters because it broadens the story beyond Carvykti, while the IEC-EC warning matters because it adds a real safety issue to monitor.
The point was not to make every signal equally important. The goal was to judge which developments actually changed the strength, weakness, or direction of the Legend Biotech story.
This structured aggregation of recent signals is what makes the final conclusion clearer. Legend Biotech still depends heavily on Carvykti, but the evidence now supports a more complete view: the product is scaling, manufacturing looks stronger, profitability is becoming more credible, and the pipeline has started to matter again.
At the same time, competition, safety, litigation, and dilution remain real watch items. We treated those as current risks to monitor rather than reasons to overturn the overall conclusion, because they have not visibly broken Carvykti’s growth or Legend’s operating progress so far.
We are independent from Legend Biotech and Johnson & Johnson. We do not hold shares or other economic exposure to Legend Biotech, and this analysis is for informational purposes only. It should not be read as investment advice or as a recommendation to buy, sell, or hold any security.
Key sources used for this analysis include: Legend Biotech’s Q1 2026 results and Carvykti sales update, Legend Biotech’s June 2026 public offering pricing, Legend Biotech’s LB2501 EHA 2026 announcement, the EHA 2026 LB2501 abstract, Legend Biotech’s LB2501 proof-of-concept update, Legend Biotech’s LB2102 and ASCO 2026 Carvykti data, the FDA Carvykti product page, the FDA boxed warning for IEC-EC after Carvykti, the Mayo Clinic / Blood Advances IEC-EC retrospective study, J&J MedicalConnect’s summary on Carvykti IEC-EC, Gilead’s acquisition of Arcellx and anito-cel, Kite / Gilead’s iMMagine-1 anito-cel ASH 2025 data, Legend Biotech’s investor profile, employee count, and U.S.-centered positioning, Legend Biotech’s U.S. and EU operations page, Legend Biotech’s leadership page, Legend Biotech’s GenScript deconsolidation filing, and JUVE Patent’s report on the BMS / 2seventy / J&J / Legend Biotech European patent dispute.
In our cell therapy market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- How strong is fundraising in the cell therapy market right now?
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
- Cell Therapy: who are the top startups?
